Egypt’s Infectious diseases drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Communicable diseases are contagious and chronic illnesses caused by an infectious agent, such as bacteria, viruses, fungi, or parasites. The diseases are transmitted either directly or indirectly which causes a large number of populations to get sick. Individuals affecting with any communicable diseases often experience high fever, weakness, and muscle pain
Egypt has strong vertical programs for many priority communicable diseases, such as tuberculosis and the Expanded Programme on Immunization. The action plan for the prevention, care and treatment of viral hepatitis 2014–2018 is an example of a recent strategy where the health system response was strongly emphasized in both prevention and in the care and treatment of patients.
The country is affected by a number of vector-borne diseases of public health concern. More than 30 species of mosquito have been reported, including Anopheles, Culex, Ochlerotatus (Aedes), Culiseta, and Uranotaenia. Once highly endemic and affecting large numbers, the endemicity of schistosomiasis is now low throughout the country. Rates of HIV, Malaria, and other infectious diseases also remain low in the country. It is Polio-free and large campaigns are being carried out for Hepatitis elimination. The government is also largely focused on immunization drives carried out within one year of birth.
The growth of the communicable diseases treatment market (Sexually transmitted, Injection transmitted, NTD’s) creates an opportunity for the pharma companies to introduce novel therapy and promising pipeline drugs. Advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the demand for drugs.
In Egypt, the Hepatitis C therapeutics market is the biggest market amongst all other infectious diseases. The COVID-19 pandemic has reignited interest in infectious diseases and the focus on infection control and treatment market through vaccination will experience tremendous growth.
Across the MENA region, the nature of diseases for which there is the most treatment demand is shifting from communicable diseases to non-communicable and chronic diseases, a shift for which multinationals are well prepared. This trend has certainly reached Egypt as life expectancy is increasing with better disease management and with improved access to healthcare, rates of lifestyle-driven and chronic diseases are decreasing.
Further, the huge financial burden and patent expiration are the factors that hinder the growth of this market.